Coronavirus treatment with remdesivir to cost $2,340 per patient
Kyodo -- Jun 30
Gilead Sciences Inc. said Monday that its experimental anti-coronavirus drug remdesivir will be supplied to the governments of developed countries at what it sees as an affordable price of $2,340 per patient for a typical five-day treatment course.

The U.S. biopharmaceutical company has been donating worldwide, including to Japan, doses of the anti-viral drug that has demonstrated patient improvement in clinical trials for the disease triggered by the novel coronavirus. But it had not been clear what the price tag of the drug would be after the donations ended.

The U.S. Department of Health and Human Services said it has secured more than 500,000 treatment courses of the drug for the country's hospitals through September, which represents most of Gilead's projected production for the three months from July.

A treatment course of remdesivir is, on average, about six vials, according to the department.

Gilead said in a press release that it will charge governments $390 per vial.

News source: Kyodo
Jul 10
Japan will tighten its criteria for supporting exports of coal-fired power plants amid criticism that the practice goes against global efforts to curb global warming. (Japan Times)
Jul 05
Japanese researchers say recent volcanic activity on Nishinoshima has caused the remote island in the Pacific to increase in size. (NHK)
Jul 05
Alpine plants have come under threat of extinction from the sudden expansion of a species of dwarf bamboo in mountainous regions of Japan. (Kyodo)
Jul 03
The Japanese government will urge the closure or suspension of about 100 low-efficiency coal-fired power plants in the country by fiscal year 2030 in the face of international pressure for a transition to greener alternatives. (Nikkei)
Jul 03
Night sky watchers say what appeared to be a fireball was seen streaking over wide areas of Japan. (NHK)
Jul 02
As Japan emerges from a state of emergency, the Yokohama City Seibu Hospital, once the site of one of the worst hit hospitals of the coronavirus outbreaks, is grappling to operate alongside a virus with no treatment or cure. (Reuters)
Jul 01
The number of deaths from influenza sharply fell in urban areas in Tokyo this winter, possibly due to preventive measures taken against the new coronavirus. (NHK)
Jun 30
Gilead Sciences Inc. said Monday that its experimental anti-coronavirus drug remdesivir will be supplied to the governments of developed countries at what it sees as an affordable price of $2,340 per patient for a typical five-day treatment course. (Kyodo)
Jun 28
Health researchers have put artificial intelligence to work in crunching big data, allowing them to develop technology that can predict the future onset of around 20 diseases so people can make preventative lifestyle changes. (Japan Times)
Jun 27
Japan's railway operator is concerned that the planned opening of a super-fast magnetically levitated train system may be delayed due to a dispute with a local government. (NHK)